Role of HPV testing in clinical practice

Virus Research

Volumn 89, Issue 2, 2002, Pages 263-269

  Cuzick, Jack ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Clinical; HPV; Role

Indexed keywords

VIRUS DNA;

ADENOCARCINOMA; AUTOMATION; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER SCREENING; CARCINOGENESIS; CLINICAL PRACTICE; CONFERENCE PAPER; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; EARLY DIAGNOSIS; FOLLOW UP; HEALTH CARE COST; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MORTALITY; PATIENT CARE; PERFORMANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RELIABILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DIAGNOSIS; VIRUS INFECTION; VIRUS LOAD; WART VIRUS;

ADULT; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0036851007     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(02)00194-6     Document Type: Conference Paper

References (32)

1. Bollen L.J.M., Tjong-A-Hung S.P., van der Velden J., Mol B.W., Lammes F.B., ten Kate F.W., ter Schegget J., Bleker O.P. Human papillomavirus DNA after treatment of cervical dysplasia: low prevalence in normal cytologic smears. Cancer. 77:1996;2538-2543.
2. Bollen L.J.M., Tjong-A-Hung S.P., van der Velden J., Mol B.W., ten Kate F.W., ter Schegget J., Bleker O.P. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol. Oncol. 72:(2):1999;199-201.
3. Chua K.-L., Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol. Oncol. 66:1997;108-113.
4. Clavel C., Masure M., Bory J.-P., Puitaud I., Mangeojean C., Lorenzato M., Gabriel R., Quereux C., Birembaut P. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br. J. Cancer. 80:1999;1306-1311.
5. Clavel C., Maure M., Bory J.P., Puitaud I., Mangeojean C., Lorenzato M., Nazeyrollas P., Gabriel R., Quereux C., Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer. 84:2001;1616-1623.
6. Cox J.T. Clinical role of HPV DNA testing. Lorincz A.T., Reid R., Obstetrics and Gynecology Clinics of North America: Human Papillomavirus II. second ed. 1996;Saunders, Philadelphia.
7. Cuzick J. Viral load as a surrogate for persistence in cervical human papillomavirus infection. New Developments in Cervical Cancer Screening and Prevention. 1997;373-378 Blackwell Science, Oxford. Chapter 43.
8. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P., Anderson M., Kocjan G., Steele S.T., Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet. 345:1995;1533-1537.
9. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., Lorincz A., Chan W.-K., Krausz T., Soutter P. HPV testing in primary screening of older women. Br. J. Cancer. 81:1999;554-558.
10. Cuzick, J., Sasieni, P., Davies, P., Adams, J., Normand, C., Frater, A., van Ballegooijen, M., vand den Akker, E., 1999b. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol. Assess. 3 (14).
11. Denny L., Kuhn L., Pollack A., Wainwright H., Wright T.C. Jr. Evaluation of alternative methods of cervical cancer screen for resource-poor settings. Cancer. 89:2000;826-833.
12. Elfgren K., Bistoletti P., Dillner L., Walboomers J.M., Meijer C.J., Dillner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am. J. Obstet. Gynecol. 174:1996;937-942.
13. Gurley, M., Carter, C.D., Bounassif, S., 1999. Does HPV Status have a Role in the Management of Women with Abnormal Cervical Cytology. In: Seventeenth International Papillomavirus Conference, Charleston, SC.
14. Hart Study Group, 2001. Baseline Results for the HART Multicentre HPV Screening Study of Older Women. Nineteenth International Papillomavirus Conference September 1st-7th 2001, Florianopolis, Brazil.
15. IARC, 1995. Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 64. Human Papillomaviruses, Lyon.
16. Kjellberg L., Wadell G., Bergman F., Isaksson M., Angstrom T., Dillner J. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am. J. Obstet. Gynecol. 183:2000;1238-1242.
17. Lin C.-T., Tseng C.-J., Lai C.-H., Hsueh S., Huang K.G., Huang H.J., Chao A. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am. J. Obstet. Gynecol. 184:2001;940-945.
18. Manos M.M., Kinney W.K., Hurley L.B., et al. A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. Am. J. Obstet. Gynecol. 179:1998;497-502.
19. Nagai Y., Maehama T., Asato T., Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence. Gynecol. Oncol. 79:2000;294-299.
20. National Audit Office, 1998. The performance of the NHS cervical screening programme in England. Report by the Comptroller and Auditor General. London, Stationery Office.
21. Nobbenhuis M., Meijer C.J.L.M., van den Brule A.J.C., Rozendaal L., Voorhost F.J., Risse E.K., Verheijen R.H., Helmerhorst T.J. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer. 84:2001;796-801.
22. Nuovo G., Moritz J., Kowalik A., Chalas E., Kaplan B., Mann W. Human papillomavirus types and cervical squamous intraepithelial lesions that recur after cold-knife conization. Gynecol. Oncol. 46:1992;304-308.
23. Ratnam S., Franco E.L., Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9:2000;945-951.
24. Sasieni P., Cuzick J. Estimates of the cost impact of introducing HPV testing into a cervical screening programme. Franco E., Monsonego J., New Developments in Cervical Cancer Screening and Prevention. 1997;364-372 Blackwell Science Ltd, Oxford.
25. Sasieni P., Cuzick J., Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet. 346:1995;1566-1567.
26. Sasieni P.D., Cuzick J., Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br. J. Cancer. 73:1996;1001-1005.
27. Schiffman M., Herrero R., Hildesheim A., Sherman M.E., Bratti M., Wacholders S., Alfaro M., Hutchinson M., Morales J., Greenberg M.D. HPV DNA testing in cervical cancer screening. Results from women in a high-risk province of Costa Rica. J. Am. Med. Assoc. 283:2000;87-93.
28. ALTS Group, Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 93:2001;293-299.
29. Soutter W.P., Fletcher A. Invasive cancer of the cervix in women with mild dyskaryosis followed up cytologically. Br. Med. J. 308:1994;1421-1423.
30. Stanbridge C.M., Suleman B.A., Persad R.V., El-Khatib S. A cervical smear review in women developing cervical carcinoma with particular reference to age, false negative cytology and histologic type of the carcinoma. Int. J. Gynecol. Cancer. 2:1992;92-100.
31. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1999;12-19.
32. Womack S.D., Chirenje Z.M., Blumenthal P.D., Gaffikin L., McGrath J.A., Chipato T., Ngwalle E., Shah K.V. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. Br. J. Obstet. Gynecol. 107:2000;33-38.